Archimedes Tech SPAC Partners III (ARCI)
Market Price (3/30/2026): $9.85 | Market Cap: $-Sector: Financials | Industry: Multi-Sector Holdings
Archimedes Tech SPAC Partners III (ARCI)
Market Price (3/30/2026): $9.85Market Cap: $-Sector: FinancialsIndustry: Multi-Sector Holdings
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Low stock price volatilityVol 12M is 4.9% | Trading close to highsDist 52W High is -0.5%, Dist 3Y High is -0.5% | Key risksARCI key risks include [1] the failure to complete a business combination within its mandated timeframe, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -22%, 3Y Excs Rtn is -62% |
| Low stock price volatilityVol 12M is 4.9% |
| Trading close to highsDist 52W High is -0.5%, Dist 3Y High is -0.5% |
| Weak multi-year price returns2Y Excs Rtn is -22%, 3Y Excs Rtn is -62% |
| Key risksARCI key risks include [1] the failure to complete a business combination within its mandated timeframe, Show more. |
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ARCI | ||
| Market (SPY) | -5.3% | 79.0% |
| Sector (XLF) | -10.0% | 19.9% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ARCI | ||
| Market (SPY) | 0.6% | 79.0% |
| Sector (XLF) | -10.8% | 19.9% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ARCI | ||
| Market (SPY) | 9.8% | 79.0% |
| Sector (XLF) | -7.1% | 19.9% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ARCI | ||
| Market (SPY) | 69.4% | 79.0% |
| Sector (XLF) | 40.5% | 19.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ARCI Return | - | - | - | - | - | 0% | 0% |
| Peers Return | 0% | 0% | 0% | 0% | 0% | -19% | -19% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| ARCI Win Rate | - | - | - | - | - | 0% | |
| Peers Win Rate | 0% | 0% | 0% | 0% | 0% | 23% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| ARCI Max Drawdown | - | - | - | - | - | 0% | |
| Peers Max Drawdown | 0% | 0% | 0% | 0% | 0% | -19% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADAC, AEAQ, AIB, ALUB, BBCQ.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
ARCI has limited trading history. Below is the Financials sector ETF (XLF) in its place.
| Event | XLF | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -26.9% | -25.4% |
| % Gain to Breakeven | 36.7% | 34.1% |
| Time to Breakeven | 525 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -43.3% | -33.9% |
| % Gain to Breakeven | 76.5% | 51.3% |
| Time to Breakeven | 295 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.1% | -19.8% |
| % Gain to Breakeven | 35.2% | 24.7% |
| Time to Breakeven | 338 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -83.7% | -56.8% |
| % Gain to Breakeven | 515.2% | 131.3% |
| Time to Breakeven | 4,470 days | 1,480 days |
Compare to ADAC, AEAQ, AIB, ALUB, BBCQ
In The Past
SPDR Select Sector Fund's stock fell -26.9% during the 2022 Inflation Shock from a high on 1/12/2022. A -26.9% loss requires a 36.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Archimedes Tech SPAC Partners III (ARCI)
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
AI Analysis | Feedback
For its pharmaceutical business, imagine a smaller Eli Lilly focused on developing non-addictive pain medications.
For its appliance recycling segment, think of Best Buy's recycling services, but as a B2B offering for utility companies.
For its cellular technology segment, it's like a niche hardware provider similar to a tiny Qualcomm, making cellular modules for wireless devices.
AI Analysis | Feedback
- JAN101: A patented oral and sustained release pharmaceutical composition of sodium nitrite designed to treat pain by targeting poor blood flow in patients with diabetes or peripheral artery disease.
- Appliance Recycling and Replacement Services: Turnkey services provided for utilities and other sponsors of energy efficiency programs.
- Cellular Transceiver Modules and Wireless Services: Design, development, and sale of cellular transceiver modules and associated wireless services.
AI Analysis | Feedback
JanOne Inc. (trading as ARCI) primarily sells its products and services to other companies, not individuals directly. Based on the provided description, specific names of customer companies are not listed, but the company serves the following categories of business customers across its three segments:
- Utilities and Sponsors of Energy Efficiency Programs: For its Recycling segment, JanOne Inc. provides turnkey appliance recycling and replacement services to these entities.
- Healthcare Providers and Pharmaceutical Distributors: For its Biotechnology segment, once its lead product candidate, JAN101, is commercialized, it would typically be sold to hospitals, pharmacies, and pharmaceutical wholesalers and distributors.
- Manufacturers and Businesses Utilizing Cellular Communication Technology: For its Technology segment, the company designs, develops, and sells cellular transceiver modules and associated wireless services, primarily targeting manufacturers of devices that incorporate these modules and businesses that require these wireless services.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Archimedes Tech SPAC Partners III (ARCI) is a special purpose acquisition company (SPAC) that focuses on identifying and merging with businesses in the technology industry, particularly in artificial intelligence, cloud services, and automotive technology sectors. As a SPAC, its key risks are primarily associated with its ability to successfully execute its business objective. Here are the key risks to Archimedes Tech SPAC Partners III: *Failure to Complete a Business Combination
The most significant risk for Archimedes Tech SPAC Partners III is its potential inability to identify and complete an initial business combination within the timeframe specified in its organizational documents. If the SPAC fails to consummate a merger or acquisition within this period, it would be forced to liquidate, returning the trust account funds to its public stockholders. In such a scenario, public shareholders would only receive their initial investment back, without any return or potential upside from an operating business. *Difficulty Identifying a Suitable Acquisition Target
Archimedes Tech SPAC Partners III intends to focus its search for businesses in competitive and rapidly evolving sectors such as artificial intelligence, cloud services, and automotive technology. Identifying a suitable target company that aligns with its investment criteria, agrees to acceptable terms, and meets all regulatory requirements can be challenging. The competitive landscape for attractive acquisition targets among other SPACs and traditional buyers may make it difficult to secure a desirable merger candidate. *Redemption Risk and Potential Dilution
Even if Archimedes Tech SPAC Partners III announces a proposed business combination, public shareholders have the right to redeem their shares. High redemption rates by public shareholders can significantly reduce the amount of cash available to the combined company, potentially impacting its future operations, growth plans, or ability to raise additional capital on favorable terms. This could also lead to greater dilution for non-redeeming shareholders if additional equity financing is required.AI Analysis | Feedback
The rapid evolution and advancement of wireless communication technologies, such as the ongoing development and deployment of 5G, the emergence of 6G, and new specialized IoT communication protocols, pose a significant emerging threat to JanOne Inc.'s Technology segment. This segment designs, develops, and sells cellular transceiver modules and associated wireless services. The constant innovation from major semiconductor firms (e.g., Qualcomm, MediaTek) in integrating more functionality into System-on-Chips (SoCs) and driving down costs could lead to the accelerated obsolescence of JanOne's specific module designs. This dynamic could make it increasingly difficult for JanOne to compete on innovation, scale, or cost with larger players offering more integrated and advanced solutions, similar to how new mobile paradigms disrupted earlier hardware manufacturers.
AI Analysis | Feedback
For Archimedes Tech SPAC Partners III (ARCI), which operates as JanOne Inc., the addressable markets for its main products and services are as follows:
-
JAN101 (Non-opioid therapies for pain related to poor blood flow in diabetes or peripheral artery disease):
- The global non-opioid pain treatment market was estimated at approximately USD 48.38 billion in 2024 and is projected to reach around USD 96.25 billion by 2034.
- The global diabetic neuropathy treatment market was valued at approximately USD 5.8 billion in 2024, with a projected compound annual growth rate (CAGR) of 7.1% to reach about USD 8.74 billion by 2030.
-
Turnkey appliance recycling and replacement services:
- The global home appliance recycling market was anticipated to be approximately USD 18.8 billion in 2024 and is projected to expand to USD 38.3 billion by 2034, growing at a CAGR of approximately 7.4%. In 2025, this market is estimated to be valued at USD 21.26 billion.
-
Cellular transceiver modules and associated wireless services:
- The global cellular IoT module market is estimated to be valued at approximately USD 25.7 billion in 2025 and is projected to reach USD 210.4 billion by 2035, exhibiting a CAGR of 23.4%. The global IoT module market size was valued at USD 20.83 billion in 2024.
AI Analysis | Feedback
nullAI Analysis | Feedback
NullTrade Ideas
Select ideas related to ARCI.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | NDAQ | Nasdaq | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | JEF | Jefferies Financial | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | ALAB | Astera Labs | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | PAYO | Payoneer Global | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | FOUR | Shift4 Payments | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.89 |
| Mkt Cap | - |
| Rev LTM | 21 |
| Op Inc LTM | 1 |
| FCF LTM | - |
| FCF 3Y Avg | - |
| CFO LTM | - |
| CFO 3Y Avg | - |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | - |
| Rev Chg 3Y Avg | - |
| Rev Chg Q | -13.5% |
| QoQ Delta Rev Chg LTM | -3.0% |
| Op Mgn LTM | 2.6% |
| Op Mgn 3Y Avg | - |
| QoQ Delta Op Mgn LTM | -2.3% |
| CFO/Rev LTM | - |
| CFO/Rev 3Y Avg | - |
| FCF/Rev LTM | - |
| FCF/Rev 3Y Avg | - |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | - |
| P/S | - |
| P/EBIT | - |
| P/E | - |
| P/CFO | - |
| Total Yield | - |
| Dividend Yield | - |
| FCF Yield 3Y Avg | - |
| D/E | - |
| Net D/E | - |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.1% |
| 3M Rtn | 0.0% |
| 6M Rtn | 0.0% |
| 12M Rtn | 0.0% |
| 3Y Rtn | 0.0% |
| 1M Excs Rtn | 7.8% |
| 3M Excs Rtn | 8.1% |
| 6M Excs Rtn | 3.6% |
| 12M Excs Rtn | -11.5% |
| 3Y Excs Rtn | -61.8% |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.